US › Healthcare

Atara Biotherapeutics Inc (ATRA)

US · Healthcare · Biotechnology

$8.77+2.57%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$516,000
Revenue YoY
-99.5%
Net profit
$-4.1M
Profit YoY
-110.9%
EPS
$-0.29
EPS estimate
$-0.22
Net margin
-803.3%

EPS came in at -0.29 against a street estimate of -0.22 — a miss of 35.9%.

Key statistics

Market cap
$75.5M
Forward P/E
3.6
P/B
16.14
Book value
$-4.38
EPS (TTM)
$-1.22
52-week high
$19.14
52-week low
$3.92
50-day MA
$9.65
200-day MA
$9.42
Beta
0.09

Analyst view

Analysts rate Atara Biotherapeutics Inc a strong buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $13.67.

Shareholding

Insiders
16.92%
Institutions
52.44%

Largest institutional holders

FundStake
Adage Capital Partners Gp LLC7.77%
Redmile Group, LLC4.90%
Mackenzie Investments3.48%
Vanguard Capital Management, LLC2.42%
Point72 Asset Management, L.P.2.16%
Acadian Asset Management LLC1.45%
EcoR1 Capital, LLC1.11%
BlackRock Inc0.88%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Atara Biotherapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.